TherapeuticsMD, Inc.

Name: TherapeuticsMD, Inc. standardized financial statements, quarterly
Creator: Listed

TXMDNasdaqCIK 25743HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$869.0k, Q2 FY2026

Operating income−$816.0k, Q2 FY2026

Net income$155.0k, Q2 FY2026

TherapeuticsMD, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	period not labelled2024-03-31	Q2 FY20242024-06-30	period not labelled2024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	(53.0)	502	313	234	547	667	393	952	784	893	724	869
Cost of revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$k	(53.0)	502	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Selling, general and administrative	$k	1,590	1,476	1,322	1,582	not reported	not reported	1,081	1,551	not reported	not reported	not reported	not reported
Operating income	$k	(1,773)	(1,611)	(1,142)	(2,789)	(1,134)	(652)	(1,281)	(695)	(862)	(1,552)	(723)	(816)
Interest expense	$k	20.0	185	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$k	not reported	not reported	not reported	not reported	not reported	not reported	(32.0)	0.0	0.0	not reported	not reported	not reported
Net income	$k	(3,378)	(883)	(734)	(1,090)	(609)	252	(653)	551	152	(619)	95.0	155
Diluted EPS	$ per share	(0.32)	not reported	(0.06)	(0.09)	(0.05)	not reported	(0.06)	0.05	0.01	not reported	0.01	0.01
Basic EPS	$ per share	(0.32)	not reported	(0.06)	(0.09)	(0.05)	not reported	(0.06)	0.05	0.01	not reported	0.01	0.01

Balance sheet

Cash and equivalents$5.7m, Q1 FY2025

Shareholders' equity$27.1m, Q2 FY2026

TherapeuticsMD, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	period not labelled2024-03-31	Q2 FY20242024-06-30	period not labelled2024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	10.2	4.3	not reported	not reported	not reported	5.1	5.7	not reported	not reported	not reported	not reported	not reported
Current assets	$m	17.4	11.8	not reported	11.8	not reported	12.3	12.5	13.5	14.5	14.4	15.3	16.1
Total assets	$m	50.5	43.3	not reported	40.1	not reported	38.8	38.2	38.5	38.7	37.7	37.6	37.5
Current liabilities	$m	14.5	6.9	not reported	5.8	not reported	5.2	4.7	4.7	4.9	4.8	4.9	5.0
Total liabilities	$m	22.4	14.0	not reported	12.5	not reported	11.5	11.5	11.2	11.2	10.8	10.6	10.4
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	28.1	29.3	28.7	27.7	27.1	27.4	26.7	27.3	27.4	26.9	27.0	27.1

Cash flow

Operating cash flow$779.0k, Q2 FY2026

TherapeuticsMD, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	period not labelled2024-03-31	Q2 FY20242024-06-30	period not labelled2024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(6,028)	(4,960)	(229)	1,453	(71.0)	17.0	699	381	999	375	944	779
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)11.64m, Q2 FY2026

TherapeuticsMD, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	period not labelled2024-03-31	Q2 FY20242024-06-30	period not labelled2024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	9.3	9.8	10.2	10.7	11.5	11.5	11.5	0.0	11.6	11.6	0.0	11.6

Shares outstanding: 11.57m at Aug 9, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. Listed shows no prices and gives no investment advice.